Licensing Opportunities

Looking for ways to collaborate and engage with NCATS? Each year, NCATS researchers develop many new inventions and technologies. Staff in the NCATS Office of Strategic Alliances create unique collaborations and licenses to transfer these inventions to interested partners for further research, development and commercialization. For more information about any of the technologies listed below, please click the link to email the assigned Patenting and Licensing Manager.

Caspase Inhibitors (E-308-2009)

Potent and Selective Inhibitors of the USP1/UAF1 Deubiquitinase Complex (E-043-2013)

Anti-Malarial Agents for the Treatment of Malaria (E-751-2013/091-2016)

Small Molecule Inhibitors of Aldehyde Dehydrogenase 1A1 (E-214-2014)

Mutant IDH1 Inhibitors (E-243-2014/189-2016)

Small Molecule Inhibitors of Lactate Dehydrogenase (E-244-2014/190-2016)

Use of Ketamine Metabolite (2R,6R)-Hydroxynorketamine in Depression (E-036-2016)

Potent and Selective Cyclic Peptide Inhibitors of Phosphoglycerate Mutase as Anti-Infective Agents (E-229-2016)

NCATS' technology portfolio is currently under review and analysis. For further information please contact us at